Tumor maximal thickness, widely used as the main measurement to evaluate the size of RAH lesions, was reported to be significantly reduced in the treatment of mammalian targets with rapamycin (mTOR) inhibitors for TSC (18–20). The gene discussed is TSC1; the disease is neoplasm.